Loading
A phase 3 trial testing JSKN016 in triple-negative breast cancer, now recruiting.
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care. ClinicalTrials.gov record last updated 2026-04-16: recruiting. Enrollment is planned at 364 participants. Primary completion is estimated at 2029-03-17. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: JSKN016 Injection, Eribulin Mcsilate Injection, Vinorelbine Tartrate Injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Sacituzumab Govitecan for Injection. Registered primary measures: PFS (Progression-Free Survival); OS (Overall Survival).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares JSKN016, Alphamab Oncology, TROP2.
Shares JSKN016, Alphamab Oncology.
Shares TROP2, Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/